Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares ...

Mumbai: The Maharashtra government is considering raising the height limit for high-rise buildings in Mumbai from 120 metres to 180 metres, pending approval from the Brihanmumbai Municipal Corporation ...

Stock doesn't have any Buy/Sell Signals. Price Analysis Data details are not available.

However, absence of direct incentives for the real estate sector, such as industry status and increased tax benefits for ...

The real estate sector has pinned high hopes on the Union Budget FY 2025-26 documents and is keeping its fingers crossed regarding their expectations from the government's most important financial ...

The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Presentation slide 10 describes its revenue and planned development: Its hypoparathyroidism therapy, YORVIPATH (Palopegteriparatide, developed as TransCon PTH) was approved in the US in 08/2024.